4.7 Review

Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 13, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/jpm13060918

Keywords

pharmacogenetics; post-mortem; opioids; overdose; CYP450

Ask authors/readers for more resources

There has been an increase in accidental opioid-overdose deaths worldwide. This review focuses on the use of pharmacogenetics to predict causes of accidental opioid-overdose death, supported by a literature search and pilot study. The review includes 18 studies that demonstrate the potential of genetic testing, particularly CYP2D6, CYP2B6, and CYP3A4/5 genotyping, in identifying abnormal opioid and metabolite blood concentrations. The pilot study shows an enrichment of the CYP2B6*4 allele in methadone-overdose cases compared to the general population. These findings emphasize the importance of pharmacogenetics in determining vulnerability to opioid overdose.
There has been a worldwide substantial increase in accidental opioid-overdose deaths. The aim of this review, along with preliminary results from our pilot study, is to highlight the use of pharmacogenetics as a tool to predict causes of accidental opioid-overdose death. For this review, a systematic literature search of PubMed(& REG;) between the time period of January 2000 to March 2023 was carried out. We included study cohorts, case-controls, or case reports that investigated the frequency of genetic variants in opioid-related post-mortem samples and the association between these variants and opioid plasma concentrations. A total of 18 studies were included in our systematic review. The systematic review provides evidence of the use of CYP2D6, and to a lower extent, CYP2B6 and CYP3A4/5 genotyping in identifying unexpectedly high or low opioid and metabolite blood concentrations from post-mortem samples. Our own pilot study provides support for an enrichment of the CYP2B6*4-allele in our methadone-overdose sample (n = 41) compared to the anticipated frequency in the general population. The results from our systematic review and the pilot study highlight the potential of pharmacogenetics in determining vulnerability to overdose of opioids.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available